OCGN Ocugen, Inc.
QT6Latest market price
0.70
-0.04-5.58%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.25 | Insider Own | 8.29% | Shs Outstand | 339.11M | Perf Week | -5.00% |
| Market Cap | 238.29M | Forward P/E | — | EPS next Y | -0.27 | Insider Trans | -3.67% | Shs Float | 331.18M | Perf Month | -29.73% |
| Enterprise Value | 225.29M | PEG | — | EPS next Q | -0.06 | Short Float | 32.36% | Perf Quarter | -43.78% | ||
| Income | -82.00M | P/S | 47.66 | EPS this Y | — | Short Ratio | 17.27 | Perf Half Y | -60.96% | ||
| Sales | 5.00M | P/B | — | EPS next Y | — | ROA | -65.87% | Short Interest | 107.16M | Perf YTD | -47.95% |
| Book/sh | -0.05 | P/C | 2.38 | EPS next 5Y | — | ROE | — | 52W High | 2.73 -74.26% | Perf Year | -53.15% |
| Cash/sh | 0.29 | P/FCF | — | EPS past 3/5Y | — | ROIC | -92.68% | 52W Low | 0.69 1.71% | Perf 3Y | 87.14% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 25.99% — | Gross Margin | — | Volatility | 8.08% 7.07% | Perf 5Y | -91.55% |
| Dividend TTM | — | EV/Sales | 45.06 | EPS Y/Y TTM | — | Oper. Margin | -1504.43% | ATR (14) | 0.06 | Perf 10Y | -99.58% |
| Dividend Ex-Date | — | Quick Ratio | 0.80 | Sales Y/Y TTM | 25.00% | Profit Margin | -1786.27% | RSI (14) | 28.53 | Recom | 2.17 |
| Dividend Gr. 3/5Y | — | Current Ratio | 0.80 | EPS Q/Q | -40.00% | SMA20 | -16.91% | Beta | 1.98 | Target Price | 5.00 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | 0.00% | SMA50 | -32.04% | Rel Volume | 0.82 | Prev Close | 0.74 |
| Employees | 116 | LT Debt/Eq | — | Earnings | Nov 04 | SMA200 | -50.80% | Avg Volume | 6.55M | Price | 0.70 |
| IPO Date | Dec 03, 2014 | Option/Short | No / No | EPS/Sales Surpr. | -31.25% 67.41% | Net Debt/EBITDA | — | Volume | 5,405,165 | Change | -5.58% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Mar-01-23 | Upgrade | Chardan Capital | Neutral → Buy | |
| Aug-23-22 | Initiated | Mizuho | Buy | $5.00 |
| Aug-15-22 | Reiterated | HC Wainwright & Co. | Buy | |
| Jun-18-22 | Reiterated | Cantor Fitzgerald | Neutral | $4.50 |
| May-08-22 | Reiterated | Chardan Capital | Neutral | $3.50 |
| Apr-25-22 | Reiterated | Roth Capital | Neutral | |
| Jun-11-21 | Downgrade | Roth Capital | Buy → Neutral | |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | |
| Feb-09-21 | Downgrade | Chardan Capital | Buy → Neutral | |
| Feb-04-21 | Upgrade | HC Wainwright & Co. | Neutral → Buy |
Latest News· Times ET
Oct-29-26
Oct-22-26
Oct-22-2607:00AM
Oct-14-26
Oct-14-2606:30AM
Oct-08-26
Oct-08-2602:49PM
Oct-07-26
Oct-07-2602:37PM
Oct-06-26
Oct-06-2607:02AM
Sep-30-26
Sep-29-26
Sep-29-2607:02AM
Sep-25-26
Sep-25-2607:02AM
Sep-16-26
Sep-16-2612:02AM
Sep-11-26
Sep-09-26
Sep-02-26
Sep-01-26
Sep-01-2607:02AM
Company
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5 | 4 | 4 | 6 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 2 | 2 | 1 | — | — | — | — | — | |
| Gross Profit | 5 | 2 | 2 | 5 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 29 | 28 | 27 | 32 | — | — | — | — | — | |
| Research and Development | 44 | 40 | 32 | 40 | — | — | — | — | — | |
| Other Operating Expense | 0 | -3 | -2 | -1 | — | — | — | — | — | |
| Operating Income | -69 | -63 | -55 | -66 | — | — | — | — | — | |
| Interest Expense | 7 | 5 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -4 | 0 | 1 | 2 | — | — | — | — | — | |
| Net Income Before Taxes | -82 | -68 | -54 | -63 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -82 | -68 | -54 | -63 | — | — | — | — | — | |
| Net Income From Continuing Operations | -82 | -68 | -54 | -63 | — | — | — | — | — | |
| Net Income | -82 | -68 | -54 | -63 | — | — | — | — | — | |
| EPS (Recurring) | -0.25 | -0.23 | -0.20 | -0.26 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.25 | -0.23 | -0.20 | -0.26 | — | — | — | — | — | |
| EPS (Diluted) | -0.25 | -0.23 | -0.20 | -0.26 | — | — | — | — | — | |
| EBITDA | -70 | -60 | -52 | -62 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 47.64 | 101.25 | 54.54 | 23.38 | — | — | — | — | — | |
| Gross Margin | 100.00 | 50.00 | 50.00 | 83.33 | — | — | — | — | — | |
| Operating Margin | -1,380.00 | -1,575.00 | -1,375.00 | -1,100.00 | — | — | — | — | — | |
| Net Margin | -1,640.00 | -1,700.00 | -1,350.00 | -1,050.00 | — | — | — | — | — | |
| Shares Outstanding | 339 | 300 | 271 | 244 | — | — | — | — | — | |
| Market Capitalization | 238 | 405 | 218 | 140 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Musunuri Shankar | Chief Executive Officer | Oct 09 '26 | Sale | 0.95 | 525,991 | 499,692 | 1,030,771 | Oct 13 |
| Musunuri Shankar | Chief Executive Officer | Sep 09 '26 | Sale | 1.12 | 525,991 | 589,110 | 1,088,035 | Sep 11 |
| Johnson-Greene Treerita Essalima | Chief Financial Officer | Jun 15 '26 | Buy | 1.23 | 21,000 | 25,830 | 521,000 | Jun 17 |
| Zhang Junge | Director | Apr 01 '26 | Option Exercise | 0.79 | 194,134 | 154,303 | 1,359,316 | Apr 02 |
| Fernandes Prabhavathi | Director | Nov 26 '24 | Buy | 0.91 | 10,000 | 9,095 | 10,000 | Dec 02 |
| Castillo Kirsten | Director | Nov 22 '24 | Buy | 0.91 | 25,000 | 22,848 | 75,000 | Nov 26 |
| Zhang Junge | Director | Jun 14 '23 | Buy | 0.50 | 200,278 | 99,999 | 1,077,182 | Jun 16 |
| Musunuri Shankar | Chief Executive Officer | Feb 16 '23 | Option Exercise | 0.33 | 100,000 | 33,000 | 2,290,073 | Feb 17 |
| Musunuri Shankar | Chief Executive Officer | Feb 16 '23 | Sale | 1.08 | 100,000 | 108,000 | 2,190,073 | Feb 17 |
| Musunuri Shankar | Chief Executive Officer | Jan 17 '23 | Option Exercise | 0.51 | 100,000 | 51,000 | 2,327,950 | Jan 19 |
| Musunuri Shankar | Chief Executive Officer | Jan 17 '23 | Sale | 1.28 | 100,000 | 128,000 | 2,227,950 | Jan 19 |
| Musunuri Shankar | Chief Executive Officer | Dec 16 '22 | Option Exercise | 0.51 | 95,809 | 48,863 | 848,349 | Dec 20 |
| Musunuri Shankar | Chief Executive Officer | Dec 16 '22 | Sale | 1.43 | 95,809 | 137,007 | 752,540 | Dec 20 |
| Musunuri Shankar | Chief Executive Officer | Oct 14 '22 | Option Exercise | 0.51 | 100,000 | 51,000 | 852,540 | Oct 14 |
| Musunuri Shankar | Chief Executive Officer | Oct 14 '22 | Sale | 1.66 | 100,000 | 166,000 | 752,540 | Oct 14 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.